-
Innovation Ranking
NewInnovation Ranking – Cidara Therapeutics Inc
Cidara Therapeutics Inc (Cidara) formerly K2 Therapeutics Inc is a biotechnology company. The company discovers, develops and commercializes novel anti-infectives including immunotherapies. Its pipeline products include rezafungin for the treatment of invasive fungal disease and CD388 for treating influenza. Cidara is investigating RSV AVC program for the treatment of respiratory syncytial virus (RSV), HIV AVC for human immunodeficiency viruses (HIV), CoV AVC for pan coronavirus. The company’s proprietary Cloudbreak, an antiviral platform for the fight against life-threatening infectious diseases that...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rezafungin Acetate in Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rezafungin Acetate in Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rezafungin Acetate in Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rezafungin Acetate in Fungal Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rezafungin Acetate in Fungal Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rezafungin Acetate in Fungal Infections Drug Details: Rezafungin acetate (Rezzayo) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rezafungin Acetate in Aspergillosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rezafungin Acetate in Aspergillosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rezafungin Acetate in Aspergillosis Drug Details: Rezafungin acetate (Rezzayo) is an antifungal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avelumab in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avelumab in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Avelumab in Metastatic Colorectal Cancer Drug Details: Avelumab (MSB-0010718C, Bavencio) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AGI-134 in Melanoma Drug Details: AGI-134 is under development for the treatment of solid tumors,...
-
Product Insights
Zika Virus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Zika Virus Infections - Drugs In Development, 2023’, provides an overview of the Zika Virus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Zika Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenza A Virus, H1N1 Subtype Infections - Drugs In Development, 2023’, provides an overview of the Influenza A Virus, H1N1 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Seasonal Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Seasonal Influenza - Drugs In Development, 2023’, provides an overview of the Seasonal Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seasonal Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Middle East Respiratory Syndrome (MERS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Middle East Respiratory Syndrome (MERS) - Drugs In Development, 2023’, provides an overview of the Middle East Respiratory Syndrome (MERS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...